TaiRx, Inc.
TWO: 6580.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Du-Shieng Chien
- Employees
- 29
- Headquarters
- Taipei City, Taiwan
- IPO year
- 2017
- Market cap
- NT$1.8B
- Website
- https://www.trx.com.tw
Loading 6580…
Loading profile data…Frequently asked questions about 6580
What does TaiRx, Inc. (6580.TWO) do?
TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to...
Where does 6580.TWO trade?
TaiRx, Inc. (6580.TWO) trades on the Taipei Exchange.
What sector is 6580.TWO in?
TaiRx, Inc. (6580.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TaiRx, Inc.?
Du-Shieng Chien is the chief executive officer of TaiRx, Inc. (6580.TWO).
Where is TaiRx, Inc. headquartered?
TaiRx, Inc. is headquartered in Taiwan.
Does 6580.TWO pay a dividend?
TaiRx, Inc. (6580.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6580.TWO go public?
TaiRx, Inc. (6580.TWO) completed its initial public offering in 2017.